RFA-AG-23-005: Health Equity and the Cost of Novel Treatments for Alzheimers Disease and Related Dementias (R61/R33 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on July 1, 2022.
From the official notice on Grants.gov, last changed February 17, 2022. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR61 / R33
- Clinical trialsNot allowed
- Funded byNIA
- Median yearly award$450,069
- Typical project length3.5 years
- R61, Exploratory/Developmental Phase I. The first phase of a phased award. Moving on to the R33 phase depends on meeting agreed milestones. Other open R61 notices.
- R33, Exploratory/Developmental Grant Phase II. The second phase of a phased award, usually following an R61 or R21 phase. Other open R33 notices.
Projects funded under RFA-AG-23-005 were run by National Institute on Aging (NIA, 4 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-AG-23-005 in the NIH Guide.
Key dates
| Posted | February 17, 2022 |
|---|---|
| Deadline | July 1, 2022 |
| Archived by Grants.gov | August 6, 2022 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the program's money (73% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This Funding Opportunity Announcement (FOA) invites R61/R33 applications that address health equity, drug costs, and access to new therapeutics or repurposed drugs for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Successful applications will seek to identify preferences for pharmacological treatment among racial and ethnic minority people living with AD/ADRD, assess whether cost barriers to pharmacological care exist for racial and ethnic minority people living with AD/ADRD, and quantify expenditures and health- related quality of life (HRQoL) among people interested in receiving novel or repurposed drugs for AD/ADRD.This FOA will support a study development phase (R61) to conduct rigorous stakeholder engagement with racial and ethnic minority groups to identify, measure, and assess the demand for new and repurposed drugs, and if successful, grantees will transition to an R33 phase for implementation of rigorous modeling of costs and health-related quality of life and dissemination of model findings.
Funded under RFA-AG-23-005 so far
NIH funded 4 projects under RFA-AG-23-005 in fiscal 2023 to 2026, at 2 institutions. The median yearly award was $450,069.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Use and Impact of Novel and Repurposed Therapeutics for Alzheimer's Disease and Related Dementia in the United States | University of Southern California | 2026 | $595,655 |
| Measuring the Impact of the Value Flower and Unobserved Heterogeneity on the Cost Effectiveness and Use of Novel Treatments for Alzheimer's Disease and Related Dementias | Virginia Commonwealth University | 2026 | $580,854 |
| Use and Impact of Novel and Repurposed Therapeutics for Alzheimer's Disease and Related Dementia in Diverse Populations | University of Southern California | 2024 | $312,880 |
| Measuring the Impact of the Value Flower and Unobserved Heterogeneity on the Cost Effectiveness and Use of Novel Treatments for Alzheimer's Disease and Related Dementias | Virginia Commonwealth University | 2024 | $305,718 |
Who has won Aging Research grants before
From fiscal 2021 to 2025, Aging Research (93.866) awarded $19 billion across 11,026 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Regents of the University of California, San Francisco | California | 337 | $575 million |
| The Trustees of Columbia University in the City of New York | New York | 242 | $574 million |
| University of Southern California | California | 203 | $572 million |
| The Washington University | Missouri | 210 | $556 million |
| Regents of the University of Michigan | Michigan | 232 | $538 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-AG-23-005 still open?
No. It closed on July 1, 2022.
Who can apply for Health Equity and the Cost of Novel Treatments for Alzheimers Disease and Related Dementias (R61/R33 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Health Equity and the Cost of Novel Treatments for Alzheimers Disease and Related Dementias (R61/R33 Clinical Trial Not Allowed)?
Closed July 1, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-AG-23-005?
NIH RePORTER lists 4 projects funded under RFA-AG-23-005 in fiscal 2023 to 2026, at 2 institutions. The most were at University of Southern California, Virginia Commonwealth University.
Who has won Aging Research grants before?
The largest recipients over five fiscal years were The Regents of the University of California, San Francisco, The Trustees of Columbia University in the City of New York, University of Southern California. The program made 11,026 awards worth $19 billion in that time.
Similar open grants
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
- NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
- Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)
- HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)